Novo Nordisk A/S (BKK:NOVOB80)
Thailand · Delayed Price · Currency is THB | Market Cap | 6.83T -15.1% |
| Revenue (ttm) | 1.67T +5.6% |
| Net Income | 591.80B +4.8% |
| EPS | 133.14 +5.0% |
| Shares Out | n/a |
| PE Ratio | 11.54 |
| Forward PE | 15.31 |
| Dividend | 0.04 (2.62%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 153,149 |
| Open | 1.560 |
| Previous Close | 1.570 |
| Day's Range | 1.540 - 1.560 |
| 52-Week Range | 1.120 - 2.020 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
2 Stocks Down 8% or More That Are Screaming Buys Right Now
Intuitive Surgical's latest version of the da Vinci system could unlock important opportunities. Novo Nordisk is still well-positioned to cash in on the GLP-1 market.
Novo Nordisk owner, Quantum Foundry establish chip fab facility in Copenhagen
Quantum Foundry Copenhagen and the Novo Nordisk (NVO) Foundation announce plans to establish a new 5,300 m^2 quantum chip fabrication facility in Copenhagen. The facility will develop and scale the…
Novo Nordisk AS (NVO) Stock Up 3.7% and Still Undervalued -- GF Score: 76/100
Novo Nordisk AS (NVO) Stock Up 3.7% and Still Undervalued -- GF Score: 76/100
Pharma Giant Novo Nordisk Stock (NVO) Jumps Even as Deutsche Bank Repeats Sell Call
Shares of Novo Nordisk ($NVO) climbed by 4% to about $47 per share on Wednesday morning even after Deutsche Bank ($DB) reaffirmed its Sell rating on the Danish pharma giant’s…
Novo Nordisk Trades Nearly 58% Below GF Value as Wegovy Pill Launches in Germany
Novo Nordisk Trades Nearly 58% Below GF Value as Wegovy Pill Launches in Germany
Novo Nordisk launches Wegovy weight-loss pill in Germany
Novo Nordisk has launched its Wegovy pill in Germany, a spokesperson for the Danish drugmaker said on Tuesday, with investors keenly focused on the oral weight-loss treatment in light of intensifying...
GLP-1 weight loss drugs effective even at low starter doses
People taking popular GLP-1 obesity drugs who remain on low starter doses will lose some weight but may still experience side effects, although significantly less nausea than those who graduate to h...
600,000 seniors have signed up for obesity drugs under new Medicare program
U.S. Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz said on Monday that 600,000 seniors have signed up to receive GLP-1 weight loss medications in the first two months o...
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals buil...
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?
Novo Nordisk was first with a GLP-1 weight-loss shot, but lost the lead to Eli Lilly. Novo Nordisk was first to market with a GLP-1 pill, though Eli Lilly is now competing there, as well.
Call of the Day: Deutsche downgrades Novo Nordisk
CNBC’s “Fast Money” team discusses Deutsche's call to downgrade Novo Nordisk to sell from hold, citing a slew of negative catalysts for the rating change.
Novo Nordisk stock falls as Deutsche Bank downgrades shares to sell
Novo Nordisk shares fell on Thursday after Deutsche Bank downgraded the Danish drugmaker to Sell from Hold and lowered its price target, citing concerns over the company's growth prospects. The compan...
Novo Nordisk Stock Is Downgraded to Sell, and GLP-1s Aren't the Reason
Deutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker's ability to return to growth and navigate an impending patent cliff.
Novo Nordisk Shares Drop as Bank Downgrade Reflects Growth Concerns
The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes a...
Novo Nordisk says China’s NMPA accepted application for marketing of Wegovy
The official website of the Center for Drug Evaluation of China’s National Medical Products Administration, NMPA, shows that Novo Nordisk’s (NVO) application for the marketing of Wegovy tablets, semag...
Novo Nordisk's Weight Management Pill Approved in China
Novo Nordisk's Weight Management Pill Approved in China
Novo Nordisk downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank downgraded Novo Nordisk (NVO) to Sell from Hold with a price target of DKK 265, down from DKK 290. The firm says ziltivekimab is “now effectively out of…
Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak
While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
China drug regulator accepts Novo Nordisk's application for oral Wegovy
China's drug regulator has accepted Novo Nordisk's marketing application for the oral version of its weight-loss drug Wegovy, the Danish drugmaker said in a statement on Thursday.
Is It Too Late to Buy Novo Nordisk AS (NVO) After 3.7% Rally? GF Value Says Undervalued
Is It Too Late to Buy Novo Nordisk AS (NVO) After 3.7% Rally? GF Value Says Undervalued
PepsiCo ending coverage for prescription weight-loss drugs, Bloomberg reports
Some PepsiCo (PEP) employees were notified this week that weight-loss drugs such as Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Zepbound will no longer be covered by their company…
Novo Nordisk (NVO) -- Long-Term Growth Potential in GLP-1 Market | Argosy Investors Q2 2025
Novo Nordisk (NVO) -- Long-Term Growth Potential in GLP-1 Market | Argosy Investors Q2 2025
Novo Nordisk price target raised to DKK 275 from DKK 250 at JPMorgan
JPMorgan raised the firm’s price target on Novo Nordisk (NVO) to DKK 275 from DKK 250 and keeps a Neutral rating on the shares.
Novo Nordisk (NVO) Stock Surges on JPMorgan's Upgraded Sales Forecast
Novo Nordisk (NVO) Stock Surges on JPMorgan's Upgraded Sales Forecast
Lexicon Earns Third $10 Mln Milestone Payment From Novo For LX9851
(RTTNews) - Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company, on Monday announced that it has gained a third $10 million milestone payment from Novo Nordisk following the achievement ...